A Phase 1b, Single-Arm, Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), in Primary Membranous Nephropathy
Authors: Frank B. Cortazar, William Bonificio, Naveen Daryani, Stephen B. Thomas